冠心病治疗中波立维和泰嘉的临床对比分析

Clinical comparative analysis of Plavix and Taijia in the treatment of coronary heart disease

目的对比冠心病治疗中硫酸氢氯吡格雷片(商品名:波立维)和硫酸氢氯吡格雷片(商品名:泰嘉)的临床治疗效果。方法选取2017年12月~2018年12月收治的84例冠心病患者,以2018年5月31日前入院的患者作为研究组,以2018年5月31日后入院的患者作为对照组,每组42例。对照组患者采用波立维治疗,研究组患者采用泰嘉治疗。对比两组患者治疗前后的血液学指标[血小板计数、中性粒细胞、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)],随访1年心脏不良事件发生情况,治疗费用。结果治疗后,两组血小板计数、中性粒细胞、PT、APPT均优于治疗前,差异有统计学意义(P<0.05);但两组间对比差异无统计学意义(P>0.05)。随访1年后,研究组患者心脏不良事件发生率为7.14%,与对照组的9.52%对比,差异无统计学意义(P>0.05)。研究组患者的治疗费用为(4812.3±1209.5)元,低于对照组的(6756.9±1567.5)元,差异有统计学意义(t=6.365,P<0.05)。结论波立维与泰嘉在治疗冠心病的临床效果及不良反应方面基本相似,但泰嘉治疗费用更少,患者的经济压力较小,在临床择药时可以多考虑泰嘉。

Objective To compare the clinical effect of clopidogrel bisulphate(trade name:Plavix)and clopidogrel bisulphate(trade name:Taijia)in the treatment of coronary heart disease.Methods For 84 patients with coronary heart disease admitted from December 2017 to December 2018,patients admitted before May 31,2018 were taken as the research group,and patients admitted after May 31,2018 were taken as the control group,with 42 cases in each group.The control group was treated with Plavix,and the research group was treated with Taijia.The hematological indexes[platelet count,neutrophils,prothrombin time(PT),activated partial thromboplastin time(APTT)]before and after treatment,occurrence of adverse cardiac events after 1-year follow-up and treatment cost were compared between the two groups.Results After treatment,the platelet count,neutrophils,PT,APPT of the two groups were better than those before treatment,and the difference was statistically significant(P<0.05);but there was no statistically significant between the two groups(P>0.05).After 1-year follow-up,the incidence of adverse cardiac events of the research group was 7.14%,which had no statistically significant compared with 9.52% of the control group(P>0.05).The treatment cost of the research group was(4812.3±1209.5)yuan,which was lower than(6756.9±1567.5)yuan of the control group,and the difference was statistically significant(t=6.365,P<0.05).Conclusion The clinical effects and adverse reactions of Plavix and Taijia are basically similar in the treatment of coronary heart disease,but the treatment cost of Taijia is less,and the economic pressure of patients is less,so we can consider Taijia more in clinical selection.